Arrowhead Pharmaceuticals (ARWR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $80.00 price target.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the promising potential of Arrowhead Pharmaceuticals’ complement disease program. The positive results from the Phase 1/2 trial of ARO-C3, which is designed to treat complement-mediated renal diseases, have shown significant reductions in complement activity and proteinuria, indicating its potential as a blockbuster therapy. The data demonstrated that ARO-C3 was well-tolerated with no severe adverse events, and its durability suggests a competitive advantage with less frequent dosing compared to other therapies.
Additionally, Arrowhead’s pipeline includes other promising candidates like ARO-CFB, which could address non-renal complement-mediated diseases. The company’s strategic approach to advancing these candidates, combined with a favorable valuation using a DCF-based and SOTP-based methodology, supports the $80 price target. Despite the inherent risks in clinical development and market competition, the potential for ARO-C3 and other pipeline products to address unmet medical needs underpins the Buy recommendation.
In another report released on February 26, Piper Sandler also reiterated a Buy rating on the stock with a $45.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com